Targeting mitochondria with a ceramide compound to treat head and neck cancer

Who could benefit from this research

What this research studies

This project develops a novel C18-ceramide–based drug (LCL768) designed to accumulate in the mitochondria of head and neck cancer cells and trigger lethal mitophagy, potentially slowing tumor growth. The approach combines ceramide chemistry with mitochondrial targeting and autophagy mechanisms, plus a component (selenite) to enhance this effect. The work includes rapid development steps under a Fast-track NIH mechanism to reach preclinical milestones that could support future human trials. The focus is on improving outcomes for patients with head and neck squamous cell carcinoma who need better therapies and responses to immunotherapy.

Why it matters

Where this research is happening

• Lipo-Immuno Tech, LLC
  Mount Pleasant, United States Active

Researchers

• Principal investigator: Ogretmen, Besim — Lipo-Immuno Tech, LLC
• Study coordinator: Ogretmen, Besim

Related research

Other NIH-funded projects on the same topics.

• How some p53 gene changes help head and neck cancers spread and hide from the immune system

  Researchers are looking at whether blocking a protein called MCM5 can stop p53‑mutant head and neck cancers from becoming unstable, spreading, and weakening the immune system.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11300228

• Combining Cue-101 and engineered T cells to treat HPV-positive head and neck cancer

  Doctors are combining Cue-101 with specially engineered T cells to help people with HPV16-positive head and neck cancer by improving tumor targeting while using lower cell doses.

  NIH research Yale University · New Haven, United States · NIH-11294142

• Combining T cell therapy with a new treatment for HPV-related head and neck cancers

  This study is testing a new way to treat head and neck cancers linked to HPV by using specially modified immune cells that can find and fight the cancer, and it's for patients with HPV-positive cancers who want to explore a promising treatment option.

  NIH research Yale University · New Haven, United States · NIH-11038001

• How mutations in the TP53 gene affect cancer spread and immune response in head and neck cancers

  This study is looking at certain changes in a gene called TP53 that are often found in head and neck cancers to see how they affect how the cancer grows and avoids the immune system, with the hope of finding new treatments that could work better for patients like you.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11034107

• Using nanoscale frameworks to enhance cancer treatment and immunotherapy for head and neck cancers

  This study is exploring a new way to help people with head and neck cancers by using tiny materials that can boost radiation therapy and help the immune system fight the cancer better, aiming to improve treatment results and survival rates for patients.

  NIH research University of Chicago · Chicago, United States · NIH-10885971

• Finding ways to improve immune responses in head and neck cancers

  This study is looking at ways to improve immunotherapy for people with head and neck cancer, aiming to help more patients respond to treatment by figuring out why the immune system sometimes doesn't fight the cancer effectively.

  NIH research Yale University · New Haven, United States · NIH-10690599

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.